{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:50:12Z","timestamp":1791528612659,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Post\u2010anoxic status epilepticus (PASE) is a frequent neurologic complication following hypoxic\u2013ischemic brain injury in cardiac arrest survivors, for which no definitive treatment exists. Early \u03b3\u2010Aminobutyric Acid (GABA) augmentation using vigabatrin, a GABA\u2010transaminase inhibitor, has been proposed; however, its pharmacokinetics (PK) in this critically ill population are unknown. In this ancillary study of VIGAB\u2010STAT, an open\u2010label feasibility trial of loading dose vigabatrin via enteral tube, we evaluated vigabatrin PK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Comatose adults with electrographic status epilepticus following return of spontaneous circulation received a loading dose of vigabatrin determined by renal function (creatinine clearance (CrCl) \u2265\u200950\u2009mL\/min, 4500\u2009mg; CrCl 30\u201350\u2009mL\/min, 2250\u2009mg; CrCl &lt;\u200930\u2009mL\/min, 1125\u2009mg). Pharmacokinetic sampling occurred at 0 (pre\u2010dose), 0.5, 1, 2, 3, 6, 12, 24, 48, 72, and 168\u2010h post\u2010dose, and plasma concentrations were quantified using liquid chromatography tandem mass spectrometry. PK parameters were estimated using non\u2010compartmental analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six participants contributed 56 plasma samples. The median (range) age was 62\u2009years (22\u201368), weight 80.9\u2009kg (57.6\u2013139.9), and four (66.7%) participants were male. Loading doses were evenly distributed: 4500\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), 2250\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), and 1125\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092). Time to maximum concentration, maximum concentration, area under the concentration time curve from 0 to 24\u2009h, area under the concentration time curve from 0 to infinity and half\u2010life median (range) values were 2\u2009h (1\u20133), 38.1\u2009mg\/L (16.9\u201391.8), 431.2\u2009mg*h\/L (254.6\u2013979.3), 679.3\u2009mg*h\/L (340.3\u20131156.8), and 16.2\u2009h (9.4\u201323.9), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pioneer vigabatrin PK study in critically ill participants with PASE demonstrated absorption regardless of challenges such as enteral delivery type, co\u2010administration of gastric pH modulators, vasopressors, and anesthetics. Notably, prolonged elimination half\u2010lives and increased exposures were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70198","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:42:59Z","timestamp":1789112579000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post\u2010Anoxic Status Epilepticus"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3051-7062","authenticated-orcid":false,"given":"Nicole F.","family":"Maranchick","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, Infectious Disease Pharmacokinetics Lab, College of Pharmacy and Emerging Pathogens Institute University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-0527","authenticated-orcid":false,"given":"Katharina M.","family":"Busl","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurocritical Care, College of Medicine University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralisa","family":"Pop","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurocritical Care, College of Medicine University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Guerrero","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurocritical Care, College of Medicine University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector David Meza","family":"Comparan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurocritical Care, College of Medicine University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciola Martins","family":"Frota","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurocritical Care, College of Medicine University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Department of Neurology, Comprehensive Epilepsy Center Yale University School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Eisenschenk","sequence":"additional","affiliation":[{"name":"Department of Neurology Malcolm Randall VA Medical Center  Gainesville Florida USA"},{"name":"National Tele\u2010EEG Program VA Boston Healthcare System  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":false,"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research, Infectious Disease Pharmacokinetics Lab, College of Pharmacy and Emerging Pathogens Institute University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina B.","family":"Maciel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neurocritical Care, College of Medicine University of Florida  Gainesville Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resuscitation.2023.109985"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001123"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.3037"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.48485"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001375"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00967257"},{"key":"e_1_2_9_8_1","unstructured":"\u201cVigabatrin [package insert]. Piscataway NJ: Camber Pharmaceuticals Inc 2024\u201d."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1989.tb03456.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010199223040\u201000003"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)07404-5"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1989.tb03457.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12414"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42466\u2010022\u201000168\u2010x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNP.0000000000000806"},{"key":"e_1_2_9_16_1","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","journal-title":"Kidney International"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_9_18_1","unstructured":"\u201cM10 BIOANALYTICAL METHOD VALIDATION AND STUDY SAMPLE ANALYSIS Guidance for Industry \u201dhttp:\/\/resource.nlm.nih.gov\/9918590087306676."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552\u20104604.1993.tb04688.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691\u2010199702000\u201000014"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2018.09.006"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1091\u2010255X(02)00090\u20102"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319360\u2010000000000\u201000000"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.194"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1989.tb03455.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101157.1999.tb00820.x"},{"key":"e_1_2_9_27_1","first-page":"S7","article-title":"Pharmacology and Clinical Pharmacology of Vigabatrin","volume":"2","author":"Richens A.","year":"1991","journal-title":"Journal of Child Neurology"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163\u20107258(95)00021\u20106"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054\u2010015\u20100900\u20102"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.70198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:10:35Z","timestamp":1791526235000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/phar.70198"],"URL":"https:\/\/doi.org\/10.1002\/phar.70198","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2026-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70198"}}